Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

This study tests a triple immunotherapy combination — relatlimab, nivolumab, and ipilimumab — in patients with melanoma that has spread to the brain, aiming to see if targeting three different immune checkpoints together is more effective than existing options. **You may be eligible if...** - You are 18 or older with confirmed melanoma (not uveal/eye type) that has spread to the brain - You have at least one untreated, measurable brain tumor between 5–40 mm - You have not received prior immunotherapy targeting CTLA-4, PD-1, or LAG-3 for advanced melanoma - You are in good general health (ECOG 0–1 for asymptomatic; 0–2 for symptomatic group) **You may NOT be eligible if...** - You have uveal (eye) melanoma - All brain tumors have been previously treated with radiation or surgery - You have received prior immune checkpoint therapy for unresectable or advanced melanoma Talk to your doctor to see if this trial is right for you.